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OBJECTIVES: Recent questions have been raised about ipratropium safety in chronic 
obstructive pulmonary disease (COPD). However, these studies have failed to examine 
potential beneﬁ ts of ipratropium. Our objective was to evaluate the comparative 
effectiveness of ipratropium versus other COPD medications. METHODS: We con-
ducted a cohort study in veterans diagnosed with COPD between October 2002
and September 2003. Patients were followed up to 2.5 years for all-cause mortality,
COPD exacerbations and COPD-related hospitalizations. Time-varying medication 
exposure was determined for inhaled corticosteroids (ICS), ipratropium (IPRA), long-
acting beta-agonists (LABA), and theophylline (THEO) during follow-up. Risk 
indices were used to divide the cohort into low, moderate and high risk groups. Cox 
proportional hazards regressions were used to examine associations between medica-
tion regimen exposure and events, stratiﬁ ed by risk index and adjusted for propensity 
to use ipratropium. RESULTS: From 108,426 patients, there were 16,539 deaths, 
42,109 with an exacerbation and 14,828 with a COPD-related hospitalization.
Compared with LABA, there was a signiﬁ cant increase in the mortality risk associated
with IPRA in the moderate (HR  1.54 [95% CI 1.19–2.01] and high risk (HR  1.30
([1.09–1.55]) groups. For exacerbations, IPRA was associated with an increased
risk in the low risk group (HR  1.64 [1.40–1.92]), but not in either the moderate
(HR  0.97 [0.85–1.09]) or high risk group (HR  0.94 [0.84–1.05]). CONCLU-
SIONS: We found an increased risk of mortality associated with ipratropium that
varied by baseline risk of event. The ﬁ ndings elevate concerns about potential harms 
associated with ipratropium in COPD that do not appear to be offset by reduction in 
COPD events.
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OBJECTIVES: Asthma is a common chronic respiratory disease with an increasing
prevalence in industrialized countries. The purpose of this study was to describe
the drug utilization and spending trends for anti-asthmatic agents in the U.S. Medicaid
program. METHODS: A retrospective and descriptive study was conducted quarterly
prescriptions and reimbursement amount for each study drug in Medicaid Pharmacy 
claims ﬁ les which extracted from the Centers for Medicare & Medicaid Services 
from 1991 quarter 1 to 2007 quarter 3. The reimbursement per-prescription was 
calculated each quarter as a proxy of drug price. The study drugs included Short-
acting beta agonist (SABA), Long-acting beta agonist (LABA), Inhaled Corticosteroid 
(ICS) and Combination medication with LABA and ICS. RESULTS: The total number 
of prescriptions per quarter for asthma medications increased from 303,224 in 1991
to 1,091,201 in 2005, and dropped to 302,157 in 2007. From 1991 to 2005, the 
total number of prescriptions per quarter for SABA decreased from 278,286 to 37,965,
LABA increased from lower than 1,000 to 43,106, ICS increased from 24,938 to 
85,846 and LABA plus ICS increased from 61,477 to 924,284. The total reimburse-
ment per quarter of asthma medications increased from $23 million in 1991 to
$280 million in 2005 and dropped to $193 million in 2007. The per prescription 
price leaders among study drugs in 2007 are: Xopenex in SABA ($150 per pre-
scription), Serevent in LABA ($125 per prescription), Asmanex in ICS ($370 
per prescription) and Advair in LABA plus ICS ($184 per prescription). CONCLU-
SIONS: Total utilization and spending of asthma medications increased rapidly 
before 2005 which might primarily be due to 2002 asthma treatment guideline regard-
ing to drug use recommendations. New innovative combination drugs with LABA 
plus ICS had relatively higher per-prescription price. A signiﬁ cant decreasing of 
utilization and spending after 2005 might be due to the implementation of Medicare
Part D.
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OBJECTIVES: To assess the relationship between COPD exacerbations and controller 
therapy duration. METHODS: Data from 2 large US proprietary health claims data-
bases were pooled to construct a prevalent cohort of patients with COPD and an index
date deﬁ ned as ﬁ rst controller therapy ﬁ ll from January 1, 2004–March 31/2008.
Inclusion criteria were COPD diagnosis (ICD-9CM 491, 492, or 496), 12 months
of pre- and post-index date enrollment, 1 pharmacy claim, age 40 years, and 
no lung cancer. Controller therapy included inhaled corticosteroids, long-acting B-
agonists, ﬂ uticasone/salmeterol combination, or tiotropium bromide. Logistic regres-
sion models assessed the risk of exacerbation-related events (hospitalization, emergency
department (ED) visits, oral corticosteroid (OCS) or antibiotic prescriptions) associ-
ated with claim-identiﬁ ed therapy duration, controlling for age, sex, prior health 
care utilization, and comorbidities. RESULTS: Of the 45,657 patients (45%, men;
mean age, 60 years), 11.28% had a hospitalization; 2.70% an ED visit; 42.12%, an 
OCS prescription; and 74.99% an antibiotic prescription. The annual rate of events/
patient included 0.48 hospitalizations, 0.04 ED visits, 2.43 antibiotic prescriptions, 
and 1.18 OCS prescriptions. Controller therapy duration of claims for the cohort 
included 0–90 days in 51%, 91–180 days in 17%, 181–270 days in 11.5%, and
271–365 days in 20.4%. Compared with patients whose therapy lasted 1–90 days, 
the exacerbation event risk was no different from that for those with 91–180 days 
(odds ratio [OR], 0.98; 95%CI, 0.92,1.05), 9% higher for those with 181–270 
days (OR, 1.09; 95%CI, 1.01,1.18), and 10% higher for those with 271–365 days
(OR, 1.10; 95%CI 1.03,1.17). Similar trends were observed for each exacerbation 
event. CONCLUSIONS: The inverse relationship between controller therapy duration 
and COPD exacerbations, while potentially confounded by disease severity, suggests 
reducing symptoms earlier may improve controller therapy duration and reduce
exacerbation risk.
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OBJECTIVES: The purpose of this study was to integrate survival function with utility 
of quality of life to estimate the quality-adjusted life expectancy (QALE) and expected
loss of QALE for patients under prolonged mechanical ventilation (PMV). METHODS:
A total of 633 patients fulﬁ lled the deﬁ nition of PMV or under such a care for more
than 21 days, of which medical records were abstracted and linked to the National
Death Registry database of Taiwan to obtain the survival function. Among them we 
collected 71 subjects and assessed their quality of life by Taiwan version of EQ-5D. 
The survival function for an age and gender matched reference population was gener-
ated using the Monte Carlo method from the life table of the general population of 
Taiwan. Lifetime survival of the PMV patients were obtained using linear extrapola-
tion of a logit-transformed curve of the survival ratio between the PMV and reference 
populations. The survival probability for each time point was adjusted with the mean 
utility to obtain the QALE. RESULTS: One year survival rate were 33%. The life 
expectancy and loss of life expectancy were 32.99 months and 101.89 months in
patients with PMV, respectively. The QALE and loss of QALE in patients with slightly
clear consciousness were 12.37 quality-adjusted life months (QALM) and 85.39 
QALM, respectively. The sensitivity analysis of applying measurements from two 
proxies, namely, family care-givers and nurses, did not show a statistically signiﬁ cance
and the QALE in total patients with PMV were 9.47 and 8.54 QALM, respectively. 
CONCLUSIONS: Overall QALE of patients with PMV was poor and the loss of utility 
is big. We shall encourage per-protocol weaning procedure in the intensive care unit
and early signature for no resuscitation (DNR) when the patient’s consciousness was 
clear.
RESPIRATORY-RELATED DISORDERS – Cost Studies
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OBJECTIVES: Statins exert anti-inﬂ ammatory effects that may have a positive 
impact on asthma. This study explored the association of statin exposure with 
asthma-related events and costs. METHODS: This was a retrospective analysis of the 
12 million person Medco National Integrated Database. Adult patients receiving
inhaled corticosteroid (ICS) therapy between January 2006 to December 2006, and
q1 hospitalization/emergency room (ER) visit for asthma (ICD9 493.XX) in the previ-
ous 12 months from ﬁ rst-occurring ICS prescription were selected. Patients were then 
stratiﬁ ed by statin exposure, and were followed for 1 year to assess the risk of the 
primary event endpoint of asthma-related hospitalization/ER visit (ICD9 493.XX). 
Event costs per patient-year of follow-up (2009 $US) were calculated using age-speciﬁ c 
Healthcare Cost and Utilization Project (HCUP) data for ICD9 493.XX-related 2006 
hospitalization and 2005 ER events inﬂ ated by 5%/year. Costs were derived from 
HCUP charges applying an actual cost : charge ratio of 0.4 for hospitalization, and an 
estimated ratio of 0.6 for ER visits. RESULTS: A total of 6574 patients were studied 
(4471 statin-unexposed; 2103 statin-exposed). Overall mean o SD age was 61 o 16 
years, 29% were male, and 19% had q2 asthma hospitalization/ER events in the previ-
ous 12 months. Asthma therapy included beta agonists (short-acting 63%; long-acting 
37%) and leukotriene modiﬁ ers (38%). Hospitalization/ER event incidence was
29.4% in statin-unexposed patients versus 20.5% in statin-exposed patients [odds
ratio 0.67 (95% CI 0.58–0.76; p  0.0001) adjusted for age, gender, previous asthma 
events and asthma therapy]. Hospitalization/ER event costs per pt-year were $1354
in statin-treated patients and $1123 in untreated patients ($230; 17%). Statin 
therapy reduced both hospitalization ($252 per pt-yr; 18%) and ER ($63 per pt-yr; 
